tradmap

ANRO Earnings Alto Neuroscience, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$10 -$5 $0 2023 2024 2025
EPS
Net income (annual)
-$63M -$32M $0 2023 2024 2025
Net income
Return on equity (annual)
-42% 4% 51% 0% 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$7 -$3 $0 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26
EPS
Net income (quarterly)
-$28M -$14M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-14% 1% 16% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–14 of 14
Q2 20262026-06-30-1.342026-08-1210-Q
Q1 20262026-03-31-0.802026-05-1310-Q
FY 20252025-12-31-2.192026-03-1610-K
Q3 20252025-09-30-1.742025-11-1210-Q
Q2 20262025-06-30-1.212026-08-1210-Q
Q1 20262025-03-31-0.562026-05-1310-Q
FY 20252024-12-31-2.502026-03-1610-K
Q3 20252024-09-30-1.942025-11-1210-Q
Q2 20252024-06-30-1.322025-08-1310-Q
Q1 20252024-03-31-0.762025-05-1410-Q
FY 20242023-12-31-9.732025-03-2010-K
Q3 20242023-09-30-6.752024-11-1210-Q
Q2 20242023-06-30-4.312024-08-1310-Q
Q1 20242023-03-31-1.972024-05-1410-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.